Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
New onset diabetes after renal transplantation (NODAT) is a common and severe complication
negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the
basis of modern immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection
and graft function. However, Tacrolimus increases 2 times the risk of NODAT as compared to
CsA.